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ABSTRACT
We evaluated the efficiency of high doses of cyclophosphamide (6 g/m2) and etoposide (2 g/m2) plus filgrastim
(granulocyte colony-stimulating factor; G-CSF) to mobilize autologous hematopoietic progenitor cells in
patients with non-Hodgkin lymphoma, multiple myeloma, and Waldenström macroglobulinemia. We also
evaluated the safety of this regimen and the engraftment kinetics after myeloablative chemotherapy. Seventy-
nine patients with high-risk or relapsed/primary refractory non-Hodgkin lymphoma, multiple myeloma, or
Waldenström macroglobulinemia were treated. The mobilizing regimen was as follows: cyclophosphamide
600 mg/m2 twice daily for 10 doses, etoposide 200 mg/m2 twice daily for 10 doses (continuous; n  57) or 2
g/m2 over 10 hours on day 5 of etoposide (bolus; n  22), and G-CSF 5 g/kg/d beginning day 14. Fifty-nine
percent of patients achieved the primary end point (a CD34 cell dose of 5 million per kilogram with a single
leukapheresis). More bolus etoposide patients achieved the primary end point (86%) compared with contin-
uous etoposide patients (47%; P< .0001). The CD34 cell dose collected was greater in bolus etoposide patients
(44 million per kilogram) than in continuous etoposide patients (10.9 million per kilogram; P< .0001). Patients
took 3 weeks to recover >500/L neutrophils and >20 000/L platelets after cyclophosphamide and etopo-
side. The overall response rate was 69% for non-Hodgkin lymphoma patients and 71% for multiple myeloma/
Waldenström macroglobulinemia patients. The treatment-related mortality was 2.5%. Sixteen percent of
surviving patients experienced grade >3 nonhematologic toxicity. Patients receiving bolus etoposide had
significantly less grade >2 oral mucositis, less use of total parenteral nutrition, and less need for red blood cell
and platelet transfusions. Sixty-four patients (81%) underwent autologous hematopoietic progenitor cell
transplantation, with prompt engraftment. Four patients (5%) did not undergo autologous hematopoietic
progenitor cell transplantation because of toxicity from high-dose cyclophosphamide and etoposide. We
conclude that high doses of cyclophosphamide and etoposide combined with G-CSF are an efficient and safe
mobilizing regimen for the collection of hematopoietic progenitor cells during aggressive cytoreduction of
tumor burden in patients with lymphoid malignancies.
© 2006 American Society for Blood and Marrow Transplantation
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aNTRODUCTION
Hematopoietic progenitor cells can be mobilized
rom the bone marrow into the blood via the admin-
stration of myeloid growth factors or cytotoxic che-
otherapy [1-4]. The efﬁciency of hematopoietic pro-
enitor cell mobilization seems to be increased by t
16ytotoxic chemotherapy followed by myeloid growth
actors [5-7], albeit at a price: pancytopenia and non-
ematologic toxicities from chemotherapy, opportu-
istic infections, and increased cost. Conversely, an
dditional beneﬁt of combination-modality mobiliza-
ion is further cytoreduction of the malignancy before
a
t
a
g
s
t
t
p
s
m
[
h
b
m
m
h
m
c
G
o
c
m
p
n
p
d
a
h
m
e
m
m
h
c
G
w
b
p
f
g
c
a
p
m
a
t
t
e
r
t
ﬁ
c
t
h
M
P
h
m
w
p
a
p
h
p
m
P
d
p
d
A
r
a

t
a
a
p
v
t
w
h
T
n
d
i
ﬁ
i
(
p
h
i
l
b
a
a
t
d
d
I
E
p
c
f
L
p
Cyclophosphamide and Etoposide to Cytoreduce Lymphoid Malignancies and Mobilize Stem Cells
Butologous hematopoietic progenitor cell transplanta-
ion. However, the incremental beneﬁt of chemother-
py plus myeloid growth factor hematopoietic pro-
enitor cell mobilization to disease control in the
etting of autologous hematopoietic progenitor cell
ransplantation is uncertain.
The most common combination-modality hema-
opoietic progenitor cell mobilization regimen is cyclo-
hosphamide (4-7 g/m2) plus either granulocyte colony-
timulating factor (G-CSF; ﬁlgrastim) or granulocyte-
acrophage colony-stimulating factor (sargramostim)
8-10]. High-dose etoposide plus myeloid growth factor
as also been used as a mobilization regimen and has
een useful in individuals who did not adequately
obilize with other regimens [11,12]. Multidrug che-
otherapy plus myeloid growth factor to mobilize
ematopoietic progenitor cells is less common. For
yeloid malignancies, the combinations of high-dose
ytarabine and either etoposide or mitoxantrone plus
-CSF have proven to be highly effective mobilizers
f hematopoietic progenitor cells [13-16]. The use of
onventional-dose combination chemotherapy plus
yeloid growth factors to mobilize hematopoietic
rogenitor cells has been studied in lymphoid malig-
ancies [17-23]. The optimal mobilizing regimen in
atients with lymphoid malignancies has not yet been
etermined.
The administration of high doses of cyclophosph-
mide (150-200 mg/kg) and etoposide (1.8-4.8 g/m2)
as been established to be a safe and effective treat-
ent for patients with chemotherapy-refractory my-
loid leukemias [24]. These doses of cyclophospha-
ide and etoposide are not myeloablative, and bone
arrow recovery kinetics are quite reasonable. We
ypothesized that the combination of high doses of cy-
lophosphamide (6 g/m2) and etoposide (2 g/m2) plus
-CSF would achieve effective cytoreduction in patients
ith lymphoid malignancies with a heavy tumor burden
efore autologous hematopoietic progenitor cell trans-
lantation and act as an efﬁcient mobilizing regimen
or the collection of autologous hematopoietic pro-
enitor cells. Preliminary data demonstrated that the
ombination of high-dose cyclophosphamide (4 g/m2)
nd conventional-dose etoposide (up to 600 mg/m2)
lus myeloid growth factor effectively mobilized he-
atopoietic progenitor cells [25-29].
At the time of the design of our trial, tandem
utologous hematopoietic progenitor cell transplanta-
ion was ﬁrst being explored for multiple myeloma,
esticular cancer, and breast cancer [30-35]. Our strat-
gy was to use this intensive cytoreductive treatment
egimen as the ﬁrst part of a 2-step autologous hema-
opoietic progenitor cell transplantation in place of a
rst tandem transplantation for lymphoid malignan-
ies. The primary objective was to explore whether
his regimen would also efﬁciently and safely mobilize
ematopoietic progenitor cells. o
B&MTATERIALS AND METHODS
atient Eligibility
Patients aged 16 to 65 years with an established
istologic diagnosis of non-Hodgkin lymphoma (NHL),
ultiple myeloma, or Waldenström macroglobulinemia
ere eligible for enrollment provided that a prospective
lan to treat the patient with high-dose therapy and
utologous hematopoietic progenitor cell trans-
lantation was in place. Patients were required to
ave chemotherapy-responsive disease, deﬁned as a
artial response (PR) or better (deﬁned below) to their
ost recent cytotoxic therapy regimen or less than a
R to their ﬁrst chemotherapy regimen (primary in-
uction failure). A bone marrow aspiration and biopsy
erformed within 1 month of enrollment needed to
emonstrate 30% involvement with malignant cells.
dequate organ function was required as follows: se-
um creatinine 2 mg/dL, measured creatinine clear-
nce 40 mL/min, left ventricular ejection fraction
50%, total bilirubin 2 mg/dL, aspartate amino-
ransferase 4 times the upper limit of normal, neg-
tive serology for the human immunodeﬁciency virus,
nd a Karnofsky performance status of 80%. This
rotocol and consent form were approved by the Uni-
ersity of California, San Francisco (UCSF) Commit-
ee on Human Research. All patients gave informed,
ritten consent for participation. All patients were
ospitalized to receive protocol treatment.
reatment
Cyclophosphamide was given as a 1-hour intrave-
ous (IV) infusion at 600 mg/m2 every 12 hours for 10
oses (days 1-5). Mesna was given as a 24-hour IV
nfusion at 1.2 g/m2 daily for 6 doses (days 1-6). In the
rst 57 patients, etoposide was given as a 3-hour IV
nfusion at 200 mg/m2 every 12 hours for 10 doses
days 1-5; continuous etoposide). In the remaining 22
atients, etoposide was given as a single 2 g/m2 10-
our IV infusion on day 5 (bolus etoposide). In both
nstances, the etoposide concentration in normal sa-
ine was 0.4 mg/mL. Standard antiemetics were given
efore all chemotherapy infusions. G-CSF was given
t 5 g/kg subcutaneously daily beginning on day 14
nd continuing until the completion of blood hema-
opoietic progenitor cell collections. The CD34 cell
ose target was 5 million per kilogram. The CD34 cell
ose was determined via published guidelines of the
nternational Society of Hematotherapy and Graft
ngineering [36]. Viability markers were not routinely
erformed during the CD34 cell ﬂow cytometry.
Daily leukapheresis began when the leukocyte
ount was 5000/L. Each leukapheresis was per-
ormed via a COBE Spectra (Gambro BCT, Inc.,
akewood, CO) apheresis machine with 18 L of blood
rocessed through a Quinton dialysis catheter. A col-
ny-forming unit–granulocyte-macrophage (CFU-
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3M) assay was performed on aliquots from leuka-
heresis except when the desired CD34 cell dose was
ollected on a single leukapheresis [37]. For patients
hose total CD34 cell dose was 5 million per kilo-
ram, proceeding to autologous blood progenitor cell
ransplantation was permitted if the CFU-GM dose was
20  104/kg. Postthaw CFU-GM assays were per-
ormed on random samples quarterly for quality-assur-
nce purposes. Viability assays were not routinely per-
ormed on individual hematopoietic progenitor cell
ollections.
upportive Care
Platelet transfusions (6 units of random donor
latelets or a single donor apheresis unit) were given
hen the morning platelet count was 10 000/L
low-risk patients) or 15 000/L (standard-risk pa-
ients [standard risk was deﬁned as at least 1 of the
ollowing: fever, age 70 years, active mucositis, or
ncontrolled hypertension]). Packed red blood cell
ransfusions were given when the morning hematocrit
as 25%. Infection prophylaxis included ceftazi-
ime and amphotericin B (0.3 mg/kg/d IV) when the
bsolute neutrophil count was 500/L and was con-
inued until neutrophil recovery. Vancomycin was added
or neutropenic fever, at which time the ceftazidime was
lso switched to levoﬂoxacin. Cytomegalovirus-seroneg-
tive patients received cytomegalovirus-negative blood
roducts. Mouth care was performed 3 times a day
ith swish-and-spit salt and soda, Peridex, and am-
hotericin B (0.1 mg/mL).
utcome Measures
The primary end point was to determine the pro-
ortion of patients achieving the CD34 cell dose tar-
et of 5 million per kilogram with a single apheresis
ollection. Secondary end points included (1) response
ates from high-dose cyclophosphamide and etopo-
ide; (2) bone marrow recovery kinetics after this
reatment and engraftment kinetics of the blood he-
atopoietic progenitor cells collected during this
reatment and later used for autologous transplanta-
ion; and (3) the nonhematologic toxicities of this
ntense chemotherapy regimen. Nonhematologic tox-
cities were evaluated daily during each subject’s study
ospitalization and scored according to the UCSF
eukemia/bone marrow transplantation grading scale
s previously published [38]. An additional objective
merged during the active phase of this study. We
hanged the etoposide schedule from 10 doses over 5
ays (continuous etoposide) to a 10-hour bolus infu-
ion once on day 5 (bolus etoposide) as a result of our
bservations in a concurrent randomized study of eto-
oside schedules in patients with acute leukemia who
ere also receiving cytarabine and idarubicin [38]. Inhis concurrent study, bolus etoposide produced sig- o
18iﬁcantly less oral mucositis and signiﬁcantly less use
f total parenteral nutrition and parenteral narcotics
han continuous etoposide. We wished to reduce oral
ucosal toxicity in our patients but needed to estab-
ish that the etoposide schedule change had no adverse
ffects on blood hematopoietic progenitor cell pro-
urement efﬁciency, bone marrow recovery kinetics,
r post–autologous transplantation engraftment kinetics.
Patients with NHL were staged within 1 month of
tudy treatment with physical examination, computed
omographic scans of chest, abdomen, and pelvis, and
bilateral bone marrow aspiration and biopsy. Pa-
ients with multiple myeloma or Waldenström mac-
oglobulinemia were staged within 1 month of study
reatment with a unilateral bone marrow aspiration
nd biopsy, skeletal survey, serum quantitative immu-
oglobulin measurement, and serum and urine pro-
ein electrophoresis. Quantitation of a 24-hour urine
araprotein was performed when a urine paraprotein
as present. Restaging of all patients took place (iden-
ical to that described previously, except that no bone
arrow biopsy was performed in NHL patients with a
egative pretreatment bone marrow biopsy) 1 month
fter blood hematopoietic progenitor cell procurement.
esponse Criteria
The response criteria for NHL were as follows:
omplete response (CR), no detectable disease on
hysical examination, computed tomographic scan, or
one marrow biopsy; and PR, a 50% reduction in
he sum of bidimensional products of the perpendic-
lar diameters of measurable lymphoma masses and
mprovement in the bone marrow inﬁltration with
ymphoma compared with baseline (if the marrow was
nvolved at baseline). Progressive disease (PD) for
HL was deﬁned as a 25% increase (from nadir) in
he sum of the bidimensional perpendicular diameter
roducts of measurable lymphoma masses and/or a
25% increase in the percentage of bone marrow
nvolvement with lymphoma and/or any new lym-
homa masses. Response criteria for multiple my-
loma and Waldenström macroglobulinemia were as
ollows: CR, no detectable serum or urine parapro-
eins based on protein electrophoresis, no new skeletal
esions on plain radiographs, and bone marrow aspi-
ation and biopsy with 5% plasma cells or 5%
ymphocytes. A PR was a 50% decrease in serum
araprotein (as well as a 90% decrease in 24-hour
rine paraprotein if present at baseline), no new skel-
tal lesions on plain radiographs, and improvement in
he bone marrow inﬁltration of malignant cells com-
ared with baseline. PD for multiple myeloma or
aldenström macroglobulinemia was a 25% in-
rease (from nadir) in serum and/or urine quantitative
araprotein and/or a25% increase in the percentage
f bone marrow involvement and/or new skeletal lytic
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Cyclophosphamide and Etoposide to Cytoreduce Lymphoid Malignancies and Mobilize Stem Cells
Besions on plain radiographs. For all study patients,
table disease was that which did not meet criteria for
R, PR, or PD. Treatment-related mortality was de-
ned as any noncancer death during the study hospi-
alization.
The accrual goal was 50 patients to adequately
ssess the efﬁciency of blood hematopoietic progeni-
or cell collection, nonhematologic toxicities, and
one marrow recovery kinetics after high-dose cyclo-
hosphamide and etoposide. An additional 22 patients
ere enrolled to assess the effect of switching from
ontinuous etoposide to bolus etoposide on these out-
omes. The Student t test was used to compare con-
able 1. Patient Demographics
Patient Features
All
Patients
Continuous
Etoposide
Bolus
Etoposide
atients (n) 79 57 22
ge (y) 49.1 (21-70) 49.7 (21-70) 47.5 (31-64)
ex
Male 53 (67%) 42 (74%) 11 (50%)
Female 26 (33%) 15 (26%) 11 (50%)
iagnosis
NHL 36 (46%) 27 (47%) 9 (41%)
Indolent 2 2 0
Aggressive 34 25 9
Multiple myeloma 39 (49%) 26 (46%) 13 (59%)
Waldenström
macroglobulinemia 4 (5%) 4 (7%) 0 (0%)
isease status (n)
NHL
CR1 4 3 1
PR1 13 9 4
PIF 7 6 1
CR2 or greater 2 1 1
PR2 or greater 6 5 1
SD2 2 1 1
Unknown 2 2 0
Myeloma/Waldenström
macroglobulinemia
CR1 7 6 1
PR1 27 19 8
SD1 2 1 1
PR2 or greater 7 4 3
ata are median (range) or n (%).
R indicates complete remission; PR, partial remission; PIF, pri-
mary induction failure; SD, stable disease; NHL, non-Hodgkin
lymphoma.
able 2. Blood Hematopoietic Progenitor Cell Procurement
Parameter All Patients
ingle collection to reach target 41/69 (59%)
otal collections 1 (1-12)
ay of therapy of first leukapheresis 24 (19-75)
D34 cell dose (106/kg) 18.3 (1.3-161)
FU-GM dose (104/kg) 109 (7.5-1242)
ata are n (%) or median (range).
FU-GM indicates colony-forming unit–granulocyte-macrophage.
B&MTinuous variables between continuous and bolus eto-
oside groups, and contingency table analysis by using
he Fisher exact test was used for categorical variables.
aplan-Meier probabilities were used to determine
vent-free survival (EFS) and overall survival (OS) of
tudy participants [39].
ESULTS
atient Characteristics
Between January 1992 and July 1999, 80 patients
ere enrolled on this protocol (Table 1). One patient
id not receive protocol treatment per physician dis-
retion and was excluded from analysis. Nearly half of
he patients had NHL, and the other half had multiple
yeloma or Waldenström macroglobulinemia. Eleven
atients (14%) were treated in ﬁrst CR (scheduled for
utologous hematopoietic progenitor cell transplanta-
ion because of high-risk features [NHL] or the diag-
osis of multiple myeloma or Waldenström macro-
lobulinemia).
ematopoietic Progenitor Cell Procurement
Forty-one (59%) of 69 evaluable patients achieved
he CD34 cell dose target of 5 million per kilogram
ith a single leukapheresis procedure (Table 2). A
igniﬁcantly higher proportion (19/22; 86%) achieved
he target with a single leukapheresis after bolus eto-
oside compared with continuous etoposide (22/57,
7%; P  .0001). The median number of leukaphere-
is procedures to achieve the CD34 cell target was 1
range, 1-12) and was not signiﬁcantly different
etween the continuous and bolus etoposide
roups, although there was a trend that favored bolus
toposide (Table 2). If the CD34 cell dose target was
.5 or 3.5 million per kilogram (more typical targets at
he time of this trial design), 82% and 78% of patients,
espectively, would have achieved this target with a
ingle apheresis (range for both, 1-8 aphereses). Six
8%) of 79 patients never achieved the CD34 cell
arget dose of 5 million per kilogram.
The median CD34 cell dose collected was 18.3
illion per kilogram (range, 1.3-93). Four patients
Etoposide Schedule
P Value
Continuous
(n  57)
Bolus
(n  22)
22/47 (47%) 19/22 (86%) <.0001
2 (1-12) 1 (1-7) .052
25 (20-39) 22 (19-75) .98
10.9 (1.3-93) 44.2 (3.4-161) <.0001
109 (7.5-1242) 165 (54-860) .81319
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35%) achieved a CD34 cell dose between 2 and 5
illion per kilogram. Two patients (2.5%) achieved a
D34 cell dose of 2 million per kilogram. Four
8%) of 49 patients achieved a CFU-GM dose 20 
04/kg (2 of these 4 had CD34 cell doses 2 million
er kilogram). The total CD34 cell dose was greater
fter bolus etoposide compared with continuous eto-
oside (P  .0001; Table 2), but the quality of these
D34 cells, as measured by CFU-GM assay, was not
ifferent (Table 2). The quality of hematopoietic pro-
enitor cells, as measured by the CFU-GM/CD34 cell
ose plating efﬁciency, was also no different (mean:
2.4%  10.3% for continuous etoposide versus
5.1%  11.9% for bolus etoposide; P  .56 [Student
test] and P  .33 [Mann-Whitney U test]). The
lating efﬁciency analysis could be performed only in
atients with paired CFU-GMs and CD34 cell doses
n  42 for continuous etoposide; n  6 for bolus
toposide).
ematopoietic Progenitor Cell Engraftment
Sixty-four patients (81%) underwent autologous
ematopoietic progenitor cell transplantation. Fifteen
atients (19%) did not undergo the planned autolo-
ous hematopoietic progenitor cell transplantation
ecause of disease progression (n 7), refusal (n 1),
eath before transplantation (n  2), inadequate
uantity of collected hematopoietic progenitor cells
n  2), use of a syngeneic donor (n  1), or poor
erformance status after nonspeciﬁc interstitial pneu-
onitis (n  1) or pulmonary embolism (n  1).
hus, 4 patients (5%) did not undergo autologous
ematopoietic progenitor cell transplantation because
f toxicity from high-dose cyclophosphamide and eto-
oside. One patient underwent autologous hemato-
oietic progenitor cell transplantation with a subopti-
al dose of progenitor cells (CD34 cell dose of 1.29
illion per kilogram and CFU-GM 15.8  104/kg)
nd had rapid and sustained engraftment. In patients
ho underwent transplantation, the conditioning reg-
able 3. Blood Hematopoietic Progenitor Cell Engraftment
Parameter All Pati
umber undergoing autologous
transplantation 64 (81
D34 cell dose infused (106/kg) 10.6 (1.3
FU-GM dose infused (104/kg) 58.4 (4-8
eutrophils >500/L (day of transplantation) 11 (8-2
latelets >20 000/L (day of transplantation) 15 (8-1
latelet transfusions 4.5 (1-2
ed blood cell transfusions 4.5 (0-2
ata are n (%) or median (range).
FU-GM indicates colony-forming unit–granulocyte-macrophagemen was thiotepa/etoposide/cyclophosphamide in 23 
2040], total body irradiation and melphalan in 31, cy-
lophosphamide/carmustine/etoposide in 7 [41], and
ther in 4.
Patients with large CD34 cell collections did not
eceive all of their hematopoietic progenitor cells back
t the time of transplantation, but, rather, some were
ept in reserve. Each patient’s physician determined the
D34 cell dose infused when the dose was above that
articular patient’s transplantation protocol–speciﬁed
arget dose. The median CD34 cell dose infused was
0.6 million per kilogram (1.3-93), and this did not
iffer between the continuous and bolus etoposide
roups (Table 3). Comparing continuous etoposide
atients with bolus etoposide patients, the time to
00/L neutrophils was the same, but it took a me-
ian of 4 days longer to achieve 20 000/L platelets
n bolus etoposide patients (P  .008). There was no
ifference between etoposide groups with regard to
he number of platelet and red blood cell transfusions
eeded after transplantation (Table 3).
esponse to High-Dose Cyclophosphamide
nd Etoposide
Sixty-one patients (77%) were evaluable for re-
ponse. Eighteen patients were not evaluable for re-
ponse because of treatment-related mortality (n 2),
lready in CR (n  11), or lack of data (n  5). In
atients with NHL, the responses from high-dose
yclophosphamide and etoposide were as follows: CR,
2 (46%) of 26; PR, 6 (23%) of 26; stable disease, 3
12%) of 26; and PD, 5 (19%) of 26. In multiple
yeloma and Waldenström macroglobulinemia, the
esponses were as follows: CR, 6 (17%) of 35; PR, 19
54%) of 35; stable disease, 8 (23%) of 35; and PD, 2
6%) of 35. All 11 patients in CR at study entry
emained in CR after protocol treatment.
ematopoietic Recovery after High-Dose
yclophosphamide and Etoposide
Hematopoietic recovery (absolute neutrophils
Etoposide Schedule
P Value
Continuous
(n  57)
Bolus
(n  22)
42 (74%) 22 (100%) .2
8.9 (1.3-93) 16.3 (3.4-48) .4
60.6 (4-889) 54 (9-256) .6
11 (8-27) 11 (9-29) .5
13 (8-27) 17 (8-122) .008
5.5 (1-29) 4.0 (1-21) .3
4.5 (0-17) 5.0 (2-23) .7ents
%)
-93)
89)
9)
22)
9)
3)500/L and platelets 20 000/L) occurred a me-
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Bian of 3 weeks after the beginning of high-dose
yclophosphamide and etoposide (Table 4). Neutro-
hil recovery was 1 day faster, and platelet recovery
as 3 days faster when comparing bolus etoposide
ith continuous etoposide. Patients required fewer
latelet and red blood cell transfusions after bolus eto-
oside compared with continuous etoposide (Table 4).
onhematologic Toxicity from High-Dose
yclophosphamide and Etoposide
There were 2 treatment-related deaths, both in
atients receiving continuous etoposide. One was due
o respiratory syncytial virus (RSV) pneumonitis, and
he other was due to nonspeciﬁc adult respiratory
istress syndrome. Other grade 3 nonhematologic
oxicities included pulmonary embolism (n  1), Can-
ida albicans sepsis (n  1), herpes simplex esophagitis
n  1), subarachnoid/subdural hemorrhage (n  2),
trial ﬁbrillation (n  3), nonfatal RSV pneumonitis
n  2), Bell’s palsy (n  1), gastrointestinal hemor-
hage (n  1), pericarditis/tamponade (n  2), non–Q
ave myocardial infarction (n  1), respiratory failure
ue to etoposide-induced metabolic acidosis (n  1),
nd cardiomyopathy (n 1). These events occurred in
3 patients (16%). Patients were discharged from the
ospital after 26 days (21-69 days), and no difference
as seen between continuous etoposide and bolus
toposide patients (Table 4). Continuous etoposide
roduced more oral mucositis than bolus etoposide, as
videnced by a signiﬁcantly greater proportion of pa-
ients who experienced grade 2 oral mucositis (23%
ersus 4.5%; P  .002) and a longer average duration
f total parenteral nutrition (P  .003; Table 4).
epatic, gastrointestinal, and cutaneous toxicity was
ild, with no difference seen in patients receiving
able 4. Toxicities after High-Dose Cyclophosphamide and Etoposide
Parameter
All Patie
(n  7
eutrophils >500/L (day of therapy) 21 (11-
latelets >20 000/L (day of therapy) 23 (12-
o. platelet transfusions 5 (0-3
o. RBC transfusions 6 (0-1
reatment-related mortality 2 (2.5%
ospital discharge (day of therapy) 26 (21-
ucositis
Grade 2 13 (16%
Grade 3-4 1 (1.3%
otal parental nutrition, d, mean (range) 5.2 (0-2
arental narcotics (d) 0 (0-4
aximum total bilirubin grade >2 2 (2.5%
aximum alkaline phosphatase grade >2 12 (15%
aximum gastrointestinal toxicity grade >2 0
aximum cutaneous toxicity grade >2 3 (3.8%
ata are n (%) or median (range) unless otherwise noted.
BC indicates red blood cell.ontinuous versus bolus etoposide (Table 4). d
B&MTurvival after High-Dose Cyclophosphamide
nd Etoposide
For all enrolled patients, the median EFS and OS
as 23.7 and 46.1 months, respectively. For all pa-
ients, the 1- and 5-year EFS was 65.5% 10.8% and
5.5%  10.9%, respectively. For all patients, the 1-
nd 5-year OS was 74.3%  10% and 43.2% 
2.3%, respectively. For NHL patients, the median
FS and OS were 19.6 and 37.6 months, respectively
Figure 1). For multiple myeloma/Waldenström mac-
oglobulinemia patients, the median EFS and OS
ere 27.1 and 58.8 months, respectively (Figure 1).
ISCUSSION
Our data demonstrate that high-dose cyclophos-
hamide combined with high-dose etoposide and G-
SF is a safe and effective mobilizing regimen for
ematopoietic progenitor cells in patients with lym-
hoid malignancies. Fifty-nine percent of patients
chieved the CD34 cell dose target of 5 million per
ilogram with a single leukapheresis procedure. For
ess stringent and more typical CD34 cell dose targets
f 2.5 and 3.5 million per kilogram, 82% and 78% of
atients, respectively, would have achieved these tar-
ets with a single apheresis. Only 8% of patients did
ot achieve the CD34 protocol-speciﬁed cell dose
arget with repeated leukapheresis procedures. The
edian CD34 cell dose collected was high (18.3 mil-
ion per kilogram), and patients engrafted promptly
hen their hematopoietic progenitor cells were used
or subsequent autologous hematopoietic progenitor
ell transplantation. Seventy percent of evaluable pa-
ients had a CR or PR to this mobilizing therapy; this
Etoposide Schedule
P Value
Continuous
(n  57)
Bolus
(n  22)
22 (11-32) 20.5 (17-25) <.01
24 (12-47) 20.5 (13-27) <.002
6 (1-32) 2 (0-16) <.0001
6 (0-18) 4 (0-13) .006
2 (3.5%) 0 >0.9
26 (21-69) 24 (21-54) .5
12 (21%) 1 (4.5%) <.002
1 (1.8%) 0 >0.9
7.4 (0-29) 1.0 (0-11) .003
0 (0-32) 0 (0-46) .4
2 (3.5%) 0 >0.9
10 (17.5%) 2 (9%) .3
0 0 >0.9
2 (3.5%) 1 (4.5%) >0.9nts
9)
32)
47)
2)
8)
)
69)
)
)
9)
6)
)
)
)emonstrates the cytoreductive capacity of this com-
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3ination chemotherapy. Despite the intensity of this
reatment, 82% of patients proceeded to hematopoi-
tic progenitor cell transplantation, and the treat-
ent-related mortality was only 2.5%. Only 4 patients
id not proceed to autologous hematopoietic progen-
tor cell transplantation as a result of toxicity from this
obilizing regimen.
This hematopoietic progenitor cell–mobilizing
egimen requires substantial supportive care and re-
ource allocation. Patients spent a median of 26 days
n the hospital. Patients needed a median of 6 units of
ed blood cells transfused and 5 platelet transfusions.
ighteen percent of patients experienced UCSF grade
2 oral mucositis that necessitated 5 days of total
arenteral nutrition. The toxicity to the liver, gastro-
ntestinal tract, and integument, however, was mild.
121086420
0.0
0.2
0.4
0.6
0.8
1.0
Non-Hodgkin's Lymphoma
Myeloma/Waldenstrom's
Time from Enrollment (years)
lavivrus ee r
F-tnev
E
A
15.012.510.07.55.02.50.0
0.0
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lavivruS l larev
O
B
igure 1. Event-free survival (A) and overall survival (B) of non-
odgkin lymphoma patients and multiple myeloma/Waldenström
acroglobulinemia patients receiving high-dose cyclophosphamide
nd etoposide plus ﬁlgrastim from the time of study enrollment.
atients who did not experience an event were censored at the date
f last contact. The curves represent Kaplan-Meier probabilities.he only treatment-related deaths were 2 cases of respi- p
22atory failure, 1 due to RSV pneumonitis during a winter
eason of virulent viral outbreaks. Overall, the toxicity
roﬁle of this treatment is similar to that for an autolo-
ous hematopoietic progenitor cell transplantation.
In an effort to reduce oral mucositis, we modiﬁed
ur regimen after the ﬁrst 57 patients from continuous
toposide to bolus etoposide (with the same total eto-
oside dose). We were able to conﬁrm our previous
bservation that bolus etoposide results in less grade
2 oral mucositis and less use of total parenteral
utrition [38]. Bolus etoposide also resulted in the
eed for signiﬁcantly fewer red blood cell and platelet
ransfusions. Surprisingly, bolus etoposide resulted in
greater number of collected CD34 cells compared
ith continuous etoposide, and more bolus etoposide
atients achieved their CD34 cell dose target with a
ingle leukapheresis procedure (86% versus 39%, re-
pectively; P  .0001). Even though more CD34
ells were collected after bolus etoposide, this did not
ranslate into the expected greater CFU-GM cell dose
eing collected after bolus etoposide (Table 2). Fur-
hermore, it took 4 days longer for the autologous
ematopoietic progenitor cells collected after bolus
toposide to engraft platelets compared with those
ollected after continuous etoposide (Table 3), al-
hough bolus etoposide patients required fewer plate-
et transfusions. This suggests, but does not prove,
hat the autologous hematopoietic progenitor cells
ollected after bolus etoposide might have experi-
nced some damage from the bolus dose of etoposide,
specially when it is considered that twice as many
D34 cells were infused into bolus etoposide patients
ompared with continuous etoposide patients. How-
ver, the quality of hematopoietic progenitor cells
ollected, as measured by the ratio of CFU-GM to
D34 cell dose (plating efﬁciency), was no different in
comparison of continuous and bolus etoposide pa-
ients, and this does not support the hypothesis of
ematopoietic progenitor cell damage from bolus eto-
oside. Our lack of CD34 cell viability data at the time
f hematopoietic progenitor cell collection permits
he possibility of differences in CD34 cell functional-
ty at the time of collection between continuous and
olus etoposide patients that we were otherwise un-
ble to detect. Alternate explanations are that this was
chance ﬁnding in a retrospective subgroup analysis
nd/or that this was a statistical aberration in that
ore continuous etoposide patients (n  64) under-
ent autologous hematopoietic progenitor cell trans-
lantation than bolus etoposide patients (n  22).
It is not clear from this study whether high-dose
yclophosphamide and high-dose etoposide combined
ith G-CSF is superior to other mobilizing regimens
or lymphoid malignancies. The length of hospitaliza-
ion and the incidence of signiﬁcant oral mucositis
imits the utility of this regimen compared with sim-
ler mobilizing regimens. Whether the increased cost,
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Boxicity, and resource utilization are balanced by in-
reased overall antitumor effectiveness of this 2-step
rocedure remains to be determined.
We conclude that 6 g/m2 cyclophosphamide com-
ined with 2 g/m2 etoposide and G-CSF is a safe and
fﬁcient mobilizing regimen of hematopoietic pro-
enitor cells in patients with lymphoid malignancies.
imitations of this regimen are 3 weeks of hospital-
zation and a signiﬁcant proportion of patients expe-
iencing grade 2 oral mucositis. The use of bolus
toposide rather than continuous infusion etoposide
ncreases hematopoietic progenitor cell mobilization
fﬁciency and reduces signiﬁcant oral mucositis.
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